Fas and Fas ligand interactions suppress melanoma lung metastasis

Journal of Experimental Medicine

Volumn 188, Issue 9, 1998, Pages 1717-1723

  Owen Schaub, Laurie B ^a   Van Golen, Kenneth L ^a,b   Hill, Laurie L ^a   Price, Janet E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Fas ligand; Lung microenvironment; Melanoma; Metastasis

Indexed keywords

FAS ANTIGEN; LIGAND;

ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; LUNG METASTASIS; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; LIGANDS; LUNG NEOPLASMS; MELANOMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C3H; MICE, MUTANT STRAINS; TUMOR CELLS, CULTURED;

EID: 0032476609     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.188.9.1717     Document Type: Article

References (33)

1. Thompson, C.B. 1995. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1456-1462.
2. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1169-1178.
3. French, L.E., M. Hahne, I. Viard, G. Radlgruber, R. Zanome, K. Becker, C. Müller, and J. Tschopp. 1996. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J. Cell Biol. 133:335-343.
4. Nagata, S. 1997. Apoptosis by death factor. Cell. 88:355-365.
5. Peng, S.L., M.E. Robert, A.C. Hayday, and J. Craft. 1996. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J. Exp. Med. 184:1149-1154.
6. Zörnig, M., A. Grzeschiczek, M.-B. Kowalski, K.-U. Hartmann, and T. Möröy. 1995. Loss of Fas/APO-1 receptor accelerates lymphomagenesis in Eμ L-MYC transgenic mice but not in animals infected with MoMuLV. Omogene. 10: 2397-2401.
7. Takeuchi, T., Y. Sasaki, T. Ueki, T. Kaziwara, N. Moriyama, K. Kawabe, and T. Kakizoe. 1996. Modulation of growth and apoptosis response in PC-3 and LNCAP prostate-cancer cell lines by Fas. Int. J. Cancer. 67:709-714.
8. Owen-Schaub, L.B., R. Radinsky, E. Kruzel, K. Berry, and S. Yonehara. 1994. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54:1580-1586.
9. Irmler, M., M. Thome, M. Hahne, P. Schneider, K. Hofmann, V. Steiner, J.-L. Bodmer, M. Schröter, K. Burns, C. Mattmann, et al. 1997. Inhibition of death receptor signals by cellular FLIP. Nature. 388:190-195.
10. Möller, P., K. Koretz, F. Leithhäuser, S. Brüderlein, C. Henne, A. Quentmeir, and P.H. Krammer. 1994. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer. 57:371-377.
11. Fidler, I.J. 1990. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 50:6130-6138.
12. Price, J.E., S.L. Aukerman, and I.J. Fidler. 1986. Evidence that the process of murine melanoma metastasis is sequential and selective and contains stochastic elements. Cancer Res. 46: 5172-5178.
13. Kripke, M.L. 1979. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J. Natl. Cancer Inst. 81:541-548.
14. Fidler, I.J., E. Gruys, M.A. Cifone, Z. Barnes, and C. Bucana. 1981. Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. J. Natl. Cancer Inst. 67:947-956.
15. Talmadge, J.E., and I.J. Fidler. 1982. Enhanced metastatic potential of tumor cells harvested from the spontaneous metastasis of heterogenous murine tumors. J. Natl. Cancer Inst. 69:975-980.
16. van Golen, K.L., S. Risin, A. Staroselsky, D. Berger, M.A. Tainsky, S. Pathak, and J.E. Price. 1996. Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones. Clin. Exp. Metastasis. 14:95-106.
17. Fidler, I.J. 1995. Modulation of the organ environment for treatment of cancer metastasis. J. Natl. Cancer Inst. 87:1588-1592.
18. Rusciano, D., and M.M. Burger. 1992. Why do cancer cells metastasize to particular organs? Bioessays. 14:185-194.
19. Milik, A.M., V.A. Buechner-Maxwell, J. Sonstein, S. Kim, G.D. Seitzman, T.F. Beals, and J.L. Curtis. 1997. Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen. J. Clin. Invest. 99:1082-1091.
20. van Golen, K.L., L.B. Owen-Schaub, and J.E. Price. 1996. Metastatic and nonmetastatic K1735 melanoma cells differ in Fas-mediated apoptosis and growth response to lung-conditioned medium. Proc. Am. Assoc. Cancer Res. 37:A551. (Abstr.)
21. Owen-Schaub, L.B., S. Meterissian, and R.J. Ford. 1993. Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J. Immunother. 14: 234-241.
22. Allen, P.M., and E.R. Unanue. 1984. Differential requirement for antigen processing by macrophages for lysozyme-specific T-cell hybridomas. J. Immunol. 132:1077-1079.
23. Hill, L.L., B. Perussia, P.A. McCue, and R. Korngold. 1994. Effect of human natural killer cells on the metastatic growth of human melanoma xenografts in mice with severe combined immunodeficiency. Cancer Res. 54:763-770.
24. Szaniawska, B., S. Majewski, M.J. Kaminski, K. Noremberg, M. Swierz, and P. Janik. 1985. Stimulatory and inhibitory activities of lung-conditioned medium on the growth of normal and neoplastic cells in vitro. J. Natl. Cancer Inst. 75:303-306.
25. Crowe, P.D., T.L. Van Arsdale, B.N. Walter, K.M. Dahms, and C.F. Ware. 1994. Production of lymphotoxin (LT alpha) and a soluble dimeric form of its receptor using the baculovirus expression system. J. Immunol. Methods. 168:79-89.
26. Niehans, G.A., T. Brunner, S.P. Frizelle, J.C. Liston, C.T. Salerno, D.J. Knapp, D.R. Green, and R.A. Kratze. 1997. Human lung carcinomas express Fas ligand. Cancer Res. 57: 1007-1012.
27. Mariani, S.M., B. Matiba, C. Bäumler, and P.H. Krammer. 1995. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25:2303-2307.
28. Muzio, M., A.M. Chinnaiyan, F.C. Kischkel, K. O'Rourke, A. Shevchenko, J. Ni, C. Scaffidi, J.D. Bretz, M. Zhang, R. Gentz, et al. 1996. FLICE, a novel FADD-homologous ICE/ Ced-3-like protease, is recruited to the CD95 (Fas/APO-1) death inducing signalling complex. Cell. 85:817-827.
29. Sato, T., S. Irie, S. Kitada, and J.C. Reed. 1995. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science. 268:411-415.
30. L. Immunity. 3:87-98.
31. Arase, H., N. Arase, and T. Saito. 1995. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181:1235-1238.
32. Liles, W.C., P.A. Kiener, J.A. Ledbetter, A. Aruffo, and S.J. Klebanoff. 1996. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184: 429-440.
33. Keiner, P.A., P.M. Davis, G.C. Starling, C. Mehlin, S.J. Klebanoff, J.A. Ledbetter, and W.C. Liles. 1997. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J. Exp. Med. 15:1511-1516.